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PEMBENTUKAN REKOMBINAN OTUB1 UNTUK PENURUNAN EKSPRESI 
GEN DI DALAM SEL KANSER PAYUDARA, TULANG DAN HATI 
ABSTRAK 
Kanser adalah salah satu punca utama kematian dan morbiditi di seluruh dunia. 
Penyimpangan genetik penyebab kanser telah dicirikan dengan baik seperti mutasi, 
amplifikasi gen, translokasi, kerosakan struktur dan kehilangan pemisahan kromosom. 
Dengan penggunaan teknologi genomik moden, kita kini mula memahami kompleksiti 
kanser yang sangat besar. Menariknya pemahaman biologi sel kanser dan perkembangan 
tumor secara beransur-ansur membawa kepada kaedah yang lebih baik untuk merawat 
penyakit ini. Kemunculan alat pengeditan genom menawarkan penyelesaian menarik 
untuk menangani isu ini dengan mengganggu ekspresi gen kanser. Dalam kajian ini, alat 
pengeditan genom terkini, sistem CRISPR/Cas9, digunakan untuk menunjukkan 
potensinya untuk mengganggu ekspresi gen OTUB1 dalam sel-sel kanser payudara, 
tulang dan hati. Gen OTUB1 terdapat di dalam tisu dan memainkan peranan penting 
dalam proses fisiologi dan patologi manusia. OTUB1 mempunyai kaitan yang sangat 
signifikan dengan pertumbuhan kanser. Sebelum menjalankan transfeksi, proses 
optimisasi prosedur dan efikasi transfeksi perlu dilakukan ke atas sel untuk mendapatkan 
keputusan yang optimum. Analisis mikroskop fluorescence dan flow cytometry 
menunjukkan Lipofectamine 3000 merupakan metod pilihan untuk transfeksi. Hasil 
kajian yang memberansangkan akan membolehkan kita untuk membuat siasatan lanjut 
berkenaan peranan gen OTUB1 dalam fungsi laluan isyarat dalam sel-sel kanser yang 
berbeza. Hasil kajian ini menunjukkan bahawa recombinan OTUB1 berjaya dibentuk 
untuk proses pengurangan ekspresi OTUB1 melalui sistem CRISPR / Cas9 yang 
berpotensi untuk strategi rawatan kanser di masa depan. 
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CONSTRUCTION OF RECOMBINANT OTIB1 KNOCKDOWN IN BREAST, 
BONE AND LIVER CANCER CELL LINES 
ABSTRACT 
Cancer is one of the leading causes of mortality and morbidity all over the world. 
Various types of cancer-causing genetic aberrations are well characterized such as 
mutations, gene amplification, translocation, structural deletion and chromosomal mis-
segregation. With the use of modern genomic technologies, we are now beginning to 
understand the enormous complexity of cancer. The growing understanding of cancer cell 
biology and tumor progression is gradually leading to better methods for treating the 
disease.  The emergence of genome editing tools offers an exciting solution to addressing 
this issue by disrupting expression of cancer genes. In this study, the current genome 
editing tool, CRISPR/Cas9 system, is used to demonstrate its potential in disrupting the 
expression of OTUB1 gene in breast, bone and liver cancer cells. OTUB1 gene is 
ubiquitously expressed in human tissues and play an important role in many physiological 
and pathological processes of human. OTUB1 is also strongly correlated with cancer 
progression. Prior to transfection to knockdown OTUB1, optimization of transfection 
procedure and transfection efficacy in cell lines need to be done to get optimum results. 
Analysis using fluorescence microscopy and flow cytometry showed that Lipofectamine 
3000 is a preferable method in transfection. These encouraging results will enable us to 
conduct further investigations on exploring the role of OTUB1 gene in signalling 
pathways of different cancer cells. These results showed that the recombinant DNA 
successfully constructed to knockdown OTUB1 using CRISPR/Cas9 system can be a 
promising tool for cancer treatment strategies in the future. 
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CHAPTER 1  
 
INTRODUCTION 
1.1 Cancer 
1.1.1 General Overview of Cancer 
Globally, cancer is the second leading cause of death. In 2018, an estimated 9.6 
million deaths or about 1 in 6 deaths was due to cancer (WHO, 2018). Cancer can be 
defined as a condition in which a group of cells grow abnormally and uncontrollably by 
disregarding the normal process of cell division (Hejmadi, 2010).  
Instead of dying, cancer cells grow continuously (Sudhakar, 2009).  From the 
literature, there are several types of cancers according to the type of cells they start in, 
namely carcinoma, sarcoma, leukemia, lymphoma, myeloma, brain and spinal cord 
cancers (Biplop and Arun, 2018). Moreover, cancer can be categorized into two main 
types which are benign (cancer that does not spread to its surroundings) and malignant 
(cancer cells that often metastasize through blood circulation or lymph vessels) (Biplop 
and Arun, 2018). 
Initiation and development of cancer can be influenced by external environmental 
factors and factors within the cell such as hereditary mutations, hormones and immune 
disorders (Hejmadi, 2010). All of these factors are capable of causing abnormal cell 
activity and proliferation. Nevertheless, it is essential to remember that it typically takes 
many years for these cancer-causing DNA alterations to be detected (Hejmadi, 2010). Of 
all the cancers, the three that causes the highest cancer cases are breast, liver and bone 
cancer. 
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1.1.2 Breast Cancer  
According to Anjum, Nighat and Masood (2017), breast cancer is the most frequent 
cancer among women. Breast cancer is also considered as the second leading cause of 
death in women (WHO, 2018). Furthermore, statistics in 2018 showed that more than 
600,000 women have died due to breast cancer, which accounts for about 15% of all 
cancer deaths among women in the world.  
Statistics showed that breast cancer cases are higher in developed countries 
compared to other countries (WHO, 2018). However, breast cancer is also recognized as 
a huge public health problem in most developing countries (Balekouzou et al., 2016). 
Balekouzou et al., (2016) also described that the mortality rate of breast cancer varies 
correspondingly with age, diagnosis stages, speed of treatment management, type and 
severity of the tumor, and complacency. 
Yip, Pathy and Teo (2014) reported that genetics caused an increased risk of breast 
cancer. In addition, around 15% of breast cancer patients reported family history of breast 
and ovarian cancer. Thus, mutations in BRCA1 and BRCA2 were identified as the most 
important genetic predisposed genes of breast cancer (Yip, Pathy and Teo, 2014). 
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1.1.3 Bone Cancer  
Sarcomas of the bone are uncommon malignant tumors arising from mesenchymal 
or neuroectodermal tissue (Lewin et al., 2017). The most common malignancies of bone 
are osteosarcoma, Ewing sarcoma, and chondrosarcoma (Reed et al., 2017). 
Primary malignant bone tumors comprise approximately 5% of all childhood 
cancers in European Countries including two major cancers among children and young 
adults, such as osteosarcoma and Ewing sarcoma (Gerrand et al., 2016). According to 
American Cancer Society (2019), over 40% of primary bone cancers in adults are 
chondrosarcoma.  
Usually, osteosarcoma in children starts to develop at the end of the long bone and 
around the knee. Meanwhile tumors in adults start to develop in the axial, pelvic bones 
and craniofacial bones (Gerrand et al., 2016). Several risk factors that are responsible for 
osteosarcoma development include multiple radiation therapies treatment, Paget’s disease 
of bone and germline abnormalities (Gerrand et al., 2016). 
Chondrosarcomas are malignant cartilaginous neoplasms with various 
morphological features (Hans Gelderblom, Dijkstra and Carla S. Van Rijswijk, 2008). 
Normally, these type of tumors grow slowly and infrequently metastasize to other parts 
of the body. Besides that, primary chondrosarcoma arises in pre-existing normal bone 
(Thorkildsen et al., 2019) and subdivides into the central, periosteal and peripheral 
subgroups (Stevenson et al., 2018). Non-conventional chondrosarcoma variants include 
clear cell chondrosarcoma, mesenchymal chondrosarcoma and dedifferentiated 
chondrosarcoma (Stevenson et al., 2018). 
 
 4 
 
1.1.4 Liver Cancer  
Liver cancer is a leading cause of cancer-related deaths, accounting for 2.6 million 
cases worldwide in 2018 (WHO, 2018). The main types of primary liver cancer are 
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) (Castelli, 
Pelosi and Testa, 2017).  
HCC is the main form of liver cancer (Chuang, La and Boffetta, 2009) and has the 
highest incidence and mortality rate, compared to other liver cancers. According to 
previous studies, HCC is more common among males in Asia and Africa compared to 
European countries (Castelli, Pelosi and Testa, 2017), and is increasingly becoming a 
global problem. 
The leading cause of HCC is chronic infection of Hepatitis B and C viruses (Ukawa 
et al., 2017). Other than that, the other predominant cause of HCC is contamination of 
food with aflatoxin B1 (Chuang, La and Boffetta, 2009), that damages DNA of hepatic 
cells and causes mutation of p53 tumour suppressor gene (Janevska, Chaloska-ivanova 
and Janevski, 2015). In addition, Janevska, Chaloska-ivanova and Janevski (2015) also 
described other mutations detected in HCC, such as c-KRAS gene and co-amplification 
of the cyclin D1 gene.  
In populations with a low prevalence of HBV and HCV, alcohol is an essential risk 
factor for developing HCC (Janevska, Chaloska-ivanova and Janevski, 2015). Increased 
prevalence of overweight, obesity and diabetes are also associated with an increased risk 
of HCC (Ukawa et al., 2017). 
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1.1.5 Epidemiology of Cancer  
 
Figure 1.1 Global population with cancer in 2018, showing areas with higher 
prevalence of cancer.  
 
 
According to WHO (2018), cancer is the second leading cause of death in the 
world and it is responsible for 9.6 million deaths in 2018. Furthermore, about 1 in 6 deaths 
is caused by cancer cases around the world.  
In U.S., the number of new cases of invasive breast cancer is approximately 
266,120 cases, along with approximately 63,960 cases of non-invasive breast cancer cases 
among women in 2018. At present, there are about 3 million women living with breast 
cancer. According to the statistics, about 40,920 women in the U.S. are estimated to die 
from breast cancer. 
In Australia, there was a steep increase in the number of deaths from breast cancer, 
from about 1,435 in 1968 to 2,844 in 2014. Meanwhile in 2018, approximately 17,730 
new cases were diagnosed in Australia. In 2012, around 94,000 new cases of breast cancer 
were detected among women in Africa and 48,000 died from it in sub-Saharan Africa in 
2018. 
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1.1.6 Cancer Scenario in Malaysia  
In Malaysia, cancer is becoming a serious national health problem. It is the fourth 
leading cause of medically certified deaths. In Malaysia in 2018, approximately 20,619 
new cases in males and 23,218 new cases in females with different types of cancers were 
diagnosed.  
 
Figure 2.2      Number of overall new cancer cases in 2018 in that include both sexes 
and all ages. Breast cancer makes up the most number of cancer cases in Malaysia. 
 
According to The Global Cancer Observatory (GLOBOCAN) (2018), in 
Malaysia, the most common type of new cancer cases in men are lung, colorectal and 
prostate cancer, while in women, breast, colorectal and cervix uteri cancer are the most 
common cases (Figure 1.3). Worldwide, similar statistics are seen with lung cancer being 
the most common malignancy among males (WHO, 2018). As breast cancer has the 
highest incidence rate among females in the world too, there is an increased awareness 
of wellness programmes which include screening programs, breast self-examination and 
awareness of the early symptoms of breast cancer (Lim, 2003).  
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                              MALE              FEMALE 
 
Figure 1.3      Number of new cases in males and females, including all ages in 2018. In 
male patients, lung cancer is most common, while in female, breast cancer is most 
common. 
 
The National Strategic Plan for Cancer Control Programme (NSPCCP) 2016-
2020 targets to reduce the incidence and mortality rate of cancer. This program aims to 
improve the quality of life of cancer patients by improving the cancer care and 
management from a holistic point of view (MOH, 2017). The objectives of the program 
are to initiate screening, detection and prevention program; diagnosis and treatment as 
well as rehabilitation program. In addition, these policies also focus on palliative care, 
and traditional and complementary medicine (TCM). 
However, nowadays researchers are also focused on new approaches in cancer 
treatment such as targeted therapy, which can potentially target genes involved in the 
cancer progression pathway, such as OTUB1.  
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1.2 OTUB1 
1.2.1 General Overview  
OTUB1 or ubiquitin thioesterase, also known as otubain-1, is an enzyme in 
humans that is encoded by the OTUB1 gene. This gene is located on locus 11q13.1 in 
chromosome 11. It is also a member of OTU (ovarian tumor) superfamily which is part 
of the deubiquitinating enzymes (DUBs) family. According to Mevissen et al., (2013), 
there are 16 OTU families from deubiquitinating enzymes (DUBs) family present in 
humans and expressed in a variety of human tissues, with high expression observed in the 
brain (Fagerberg et al. 2014).  Most of the ovarian tumor (OTU) family function in 
regulating cell-signaling cascades.  
OTUB1 plays an essential role in various biological processes. OTUB1 gene is 
also responsible in controlling major events in cancer cell activities such as cancer 
initiation and progression (Saldana et al., 2019).  
Several studies demonstrate that OTUB1 regulates apoptosis, therapeutic 
resistance, proliferation, migration and invasion in several cancer types (Saldana et al., 
2019).  In his study, Stanišić et al., (2009) reported that OTUB1 also interacts with ERα 
which is the main factor in the development of breast and endometrial cancers in cells. 
OTUB1 facilitates certain types of cancer such as invasion of prostate cancer cells through 
RhoA activation and stimulation of tumorigenesis in vivo (Iglesias-Gato et al., 2015). 
Other than that, according to Sun et al., (2011), this gene has been identified as a novel 
p53 regulator. Furthermore, a previous study stated that overexpression of OTUB1 can 
cause apoptosis and is capable of inhibiting cell proliferations in a p53 dependent manner. 
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According to Goncharov et al., (2013), OTUB1 stimulates cell death by 
modulation of stability of cellular inhibitor of apoptosis (c-IAP) protein. By silencing 
OTUB1, this mechanism affects IAP in an antagonist-induced apoptosis in many types of 
cancer cells and will produce a favorable effect. Thus, studies involving combined 
targeting of OTUB1 in cancer cells might lead the way for novel therapeutic approaches 
(Goncharov et al., 2013).  
Herhaus et al. (2013) showed that OTUB1 interacts specifically with 
phosphorylated SMAD2/3 after TGF- β stimulation. In this interaction, OTUB1 opposes 
p-SMAD2/3 ubiquitination and proteasomal degradation, and stimulates TGF-β 
signalling in human cells and in vivo. OTUB1 may be an essential modulator of TGF-β/ 
SMAD-controlled cell responses as it has a phosphorylation dependent target recognition 
(Herhaus et al., 2013). Thus, interfering with the OTUB1–pSMAD interaction may 
provide an important benefit against diseases with abnormal TGF-β signaling, such as 
cancer in human. 
In addition to catalytic DUB activity, OTUB1 displays a catalytic-independent, 
non-canonical activity where it inhibits the transfer of ubiquitin onto protein substrates 
by sequestration of E2 ubiquitin-conjugating enzymes (Saldana et al., 2019). Thus, 
clinical studies have associated elevated OTUB1 expression with invasiveness and 
metastasis in several tumor types including lung, breast, ovarian, glioma, colon and 
gastric.  
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Previous literature demonstrates that OTUB1 regulates many cancer-associated 
signalling pathways including MAPK, ERα, epithelial-mesenchymal transition (EMT), 
RHOa, mTORC1, FOXM1 and P53 to promote tumor cell survival, proliferation, 
invasiveness and therapeutic resistance (Saldana et al., 2019). They suggest the 
importance of modulating OTUB1 as it could play a huge role in cancer control.  
 
 
Figure 1.6      A schematic of the mechanism of OTUB1 regulates FOXM1 which 
promotes the role of OTUB1 in cancer progression. 
 
Overexpression of OTUB1 causes cancer progression and it would be important 
to investigate the role of OTUB1 by constructing a recombinant knockdown of OTUB1 
to further study its role in cancer.  
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1.2.2 Treatment of Cancer  
According to WHO (2018), established and commonly practiced cancer 
treatments include modalities such as surgery, chemotherapy and radiotherapy. The 
treatment selection is based on the existing options available at the healthcare facilities. 
To provide the best treatment, combining modalities of therapy is also practiced by the 
cancer care team to ensure an efficient treatment. 
Surgery is known as the best treatment for patients whose breast cancer has not 
metastasized (Biplop and Arun, 2018). There are differences in the breast cancer surgeries 
depending on the amount of tissue containing tumor that needs to be removed (Lee et al., 
2015). Meanwhile, chemotherapy can be given before the surgery as a neo-adjuvant with 
the purpose of shrinking the tumor size. This dual-treatment reduces the chances of cancer 
recurrence (Masood, 2016). 
Radiotherapy is a treatment in which high-energy rays are used to kill cancer cells. 
According to WHO (2008), there are two broad categories of techniques used to treat 
patients requiring radiotherapy treatment including teletherapy and brachytherapy. 
Teletherapy, also known as external beam radiation therapy, is delivered in a tertiary 
hospital on an ambulatory basis. For certain types of cancers such as invasive cancer 
cases, brachytherapy is delivered with teletherapy to cure the disease. Brachytherapy may 
be administered in a low or high dose depending on the expertise and facilities available 
(WHO, 2008). 
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Other than that, for non-Hodgkin lymphoma, targeted radionuclide therapies such 
as radioimmunotherapy (RIT) is used to relieve pain in bone metastases case, and 
selective internal radiation therapy (SIRT) is used to treat liver cancer in selected facilities 
(Ministry of Health, 2017).  
Recognizing the need to improve the treatment methods, in 2015, WHO updated 
the list of clinically proven effective treatment regimens to include 30 cytotoxic and 
adjuvant medicines (anti-cancer medicines). The efficacy, safety, quality and cost-
effectiveness of these medications were evaluated and used in conjunction with the 
approved modalities as a targeted therapy against cancer (WHO, 2018).  
According to Biplop and Arun, (2018), targeted therapies that target specific 
biological and physiological processes that are essential to tumor growth, are new 
modalities for cancer treatment. The purpose of targeted therapies, such as gene therapy, 
includes ceasing the growth and spreading of cancer cells in the body (Biplop and Arun, 
2018). Targeted therapies are dynamic enough that they can include rare cancers, and 
accommodate different mutations.  
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1.3 Gene Therapy in Cancer and CRISPR 
1.3.1 Overview of Gene Therapy 
In the field of cancer, gene therapy can be defined as the delivery of genetic 
elements to the cancer cell to correct the abnormalities in the cancer tissue or to induce 
an immune response against the cancer cells (Akbulut, Ocal and Sonugur, 2016). 
Historically, in 1989, the first gene therapy was carried out and approved by the US Food 
and Drug Administration (FDA). The protocol utilized focused on tumor infiltrating 
lymphocytes collected from advanced melanoma patients that were transduced ex vivo 
with a marker gene, then expanded in vitro and re-infused to the patients (Wirth and Ylä-
herttuala, 2014).  
For a successful gene therapy in cancer, there are some prerequisites to be 
considered carefully, such as a suitable target to be replaced or modified, a carrier to reach 
the gene of interest in the cell, a successful targeting of the vector and a sufficient 
expression of the therapeutic genes in the target cells. In addition to that, a strong 
therapeutic efficacy, and safety of treatment delivered to the patients is also mandatory 
for the success of the treatment  (Akbulut, Ocal and Sonugur, 2016). 
The approaches of gene therapy are diverse including repairing, replacing or 
deleting the culprit gene in genetic diseases, producing incapacitating mutations in 
pathogen genomes to fight infectious diseases, or inducing therapeutic effects. This 
promising therapy can be applied to a wide range of human diseases including cancer 
(Zhang et al., 2017). 
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The development of genome-editing tools such as zinc-finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs) and Clustered Regularly 
Interspaced Short Palindromic Repeat (CRISPR/Cas9) nucleases has introduced a new 
advancement to the field of human gene therapy (Meissner et al., 2018). These 
programmable nucleases produce double-strand breaks (DSBs) at the targeted gene and 
is usually repaired by non-homologous end joining (NHEJ) which results in the disruption 
of the targeted gene (Zhang et al., 2017). Furthermore, Cong et al., (2013) reported that 
CRISPR/ Cas9-mediated genome editing has been successfully employed in a variety of 
model organisms, human embryonic and induced pluripotent stem cells, as well as in 
human adult stem cells. 
According to Wirth and Ylä-herttuala, (2014) gene therapy has the advantage over 
conventional therapies as it can be administered locally with a high therapeutic dose 
without risking systemic adverse effects. On top of that, since most gene therapies are 
single time applications, they are also cost effective. 
Cancer is an accelerated and uncontrolled growth of cells that have the capacity 
to spread throughout the body. At the late stage, cancer is generally fatal. Therefore, it is 
crucial to search for a new medical advancement to help patients. Gene therapy seems to 
be an exciting strategy that has a promising future in clinical oncological practice 
(Martinez-Davila and Delgado-enciso, 2017).  
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1.3.2 CRISPR/Cas9 Systems 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), 
together with CRISPR-associated proteins (Cas) is a microbial adaptive immune system 
that uses RNA-guided nucleases to cleave foreign genetic elements (Ran et al., 2013). It 
contains a short repeating nucleotide originally found in the genome of bacteria and 
archaea and functions to eliminate exogenous genetic elements (EGEs) that combine with 
Cas proteins (Zhang et al., 2017).  
CRISPR/Cas9 can be divided into three classification systems that have been 
identified across a wide range of bacterial and archaeal hosts, wherein each system 
comprises a cluster of CRISPR-associated (Cas) genes, noncoding RNAs and a distinctive 
array of repetitive elements (Ran et al., 2013).  
The Type II CRISPR system is one of the best characterized systems consisting 
of three components, namely an endonuclease Cas9, a CRISPR RNA (crRNA) array that 
encodes the guide RNAs and a transactivating crRNA (tracrRNA) that facilitates the 
processing of the crRNA array into discrete units (Ran et al., 2013; Zhang et al., 2017).  
The crRNA and tracrRNA molecules form a duplex structure called the guide RNA 
(gRNA), that can be substituted by a synthetic fused chimeric single gRNA (sgRNA), 
which simplifies the use of CRISPR/Cas9 in genome engineering (Oude et al., 2016). 
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Figure 1.7       Schematic of the RNA-guided Cas9 nuclease. The Cas9 nuclease from S. 
pyogenes (in yellow) is targeted to genomic DNA by a sgRNA consisting of a 20-nt guide 
sequence (blue) and a scaffold (red). The guide sequence pairs with the DNA target (blue 
bar on top strand), directly upstream of a requisite 5′-NGG adjacent motif (PAM; pink). 
Cas9 mediates a DSB ~3 bp upstream of the PAM (red triangle) (Ran et al., 2013). 
 
This simplified gRNA contains two important components namely a variable 
region and a basic scaffold. The earlier form of gRNA is normally composed of 18 to 20 
nucleotides that can bind to the target DNA according to the base complementation 
pairing rule. Then, the latter form is a long scaffold-like RNA used to bind Cas9 nuclease 
and form a gRNA/Cas9 complex (Oude et al., 2016).  
Each protospacer is associated with a protospacer adjacent motif (PAM) within 
the DNA target which can vary depending on the specific CRISPR system. In this 
CRISPR-Cas system derived from Streptococcus pyogenes, the target DNA must 
immediately precede a 5′-NGG PAM (Ran et al., 2013).  
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Figure 1.8      DSB repair promotes gene editing. DSBs induced by Cas9 (yellow) can be 
repaired in one of two ways. In the error-prone NHEJ pathway, the endogenous DNA 
repair machinery causes random indels at the site of junction. The indel can result in 
frameshifts, resulting in gene knockout. Alternatively, a repair template in the form of a 
plasmid or ssODN can be supplied to leverage the HDR pathway, which allows for a high 
fidelity and precise editing (Ran et al., 2013). 
 
According to Zhang et al., (2017), the genome-editing system requires three 
nucleotides, a PAM (NGG), to enable it to be recognized and bound by the gRNA/Cas9 
complex to generate double-strand breaks (DSBs). The DSBs are repaired by non-
homologous end joining (NHEJ) or homologous directed repair (HDR) if homologous 
sequences are available (Xiao-jie et al., 2015). 
HDR leads to precise gene correction or replacement, whereas NHEJ is error 
prone correction and may induce small inserts or deletions (indels). These indels 
eventually lead to a gene disruption or gene knockdown  (Xiao-jie et al., 2015).  These 
mechanisms hold huge promise for editing any gene in any organism  (Ran et al., 2013). 
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According to Ran et al., (2013), in comparison to other designer nucleases such 
as the zinc-finger nucleases (ZFNs) and transcription activator- like effector nucleases 
(TALENs), CRISPR/Cas9 offers several potential advantages over ZFNs and TALENs, 
including the ease of customization, higher targeting efficiency and the ability to facilitate 
multiplex genome editing (Zhang et al., 2017).  
CRISPR/Cas9 is more user-friendly than ZFN and TALEN, as primers just need 
to be synthesized as gRNAs as new targets to be used with CRISPR/Cas9 (Zhang et al., 
2017). In contrast, retargeting of a different gene requires the construction of two new 
TALEN nucleases (Ran et al., 2013).  
CRISPR/Cas9 is more economical because there is a low cost for plasmid-
mediated CRISPR/Cas9, and its genome-editing technique can be achieved in 2 weeks 
(Zhang et al., 2017). Cas9 is also extremely efficient at editing several cell types and 
organisms by targeting multiple genomic loci simultaneously by co-delivering a 
combination of sgRNAs to the cells of interest (Ran et al., 2013).  
Thus, the application of CRISPR/Cas9-based gene manipulation including gene 
knockout, gene knocking, gene interference or activation and other chromosome-related 
applications, has been widely utilized in biological and biomedical research to venture 
new dimension of genetic-engineering field.  
Due to the versatility of CRISPR/Cas9, we will be using CRISPR/Cas9 to 
construct a recombinant OTUB1 knockdown in breast, bone and liver cancer cell lines to 
investigate its role as a potential therapeutic target for cancer. 
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1.4 Problem statement 
Cancer is a leading cause of death in the world with over 9.6 million deaths in 
2018. Cancer can be caused by a variety of conditions including aberration of genes. Gene 
aberration, also known as gene mutation, can be categorized into deletion, duplication, 
insertion and translocation. Many gene mutations are responsible for cancer progression, 
including OTUB1 gene. 
OTUB1 gene regulates many cancer-associated signalling pathways such as 
FOXM1 and p53. According to a previous study, overexpression of OTUB1 in cancer 
cells promotes tumor survival, proliferation, and therapeutic resistance (Saldana et al., 
2019).  Therefore in this study, we want to construct a recombinant OTUB1 knockdown 
using CRISPR/Cas9 to evaluate its potential as a therapeutic target against cancer in the 
future.  
1.5 Research Objectives 
1.5.1 Main Objective 
Constructing recombinant OTUB1 knockdown in breast, bone and liver cancer cell lines 
to investigate the suitability of OTUB1 as a potential therapeutic therapy.  
1.5.2 Specific Objectives 
1. Designing and constructing CRISPR/Cas9 to knockdown OTUB1 
2. Optimizing the transfection efficiency in MCF7, HepG2 and Saos2 cell lines using 
Lipofectamine 3000 to ensure consistent gene expression  (by using fluorescence 
microscopy and flow cytometry) 
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CHAPTER 2  
 
METHODOLOGY 
2.1 Designing and constructing of CRISPR/Cas9 to knockdown OTUB1 
The full sequence of OTUB1 gene was retrieved from NCBI Genomic Database 
(NCBI reference sequence NM_017670.2). Then, sequence prediction of gRNA was done 
in silico using gRNA design software using Target Finder (Table 2.1).  The selected 
gRNA sequence was synthesized as oligonucleotides by Integrated DNA Technologies 
(IDT).  
 
Table 2.1       Online Tools Used to Design CRISPR Guide RNA 
 
Software URL 
 
 
NCBI Sequence 
Database 
https://www.ncbi.nlm.nih.gov/nuccore/ 
 
 
 
 
Target finder 
 
https://crispr.mit.edu 
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2.1.1      Cloning of CRISPR nuclease into expression vector 
gRNA was cloned into a Cas9 humanized expression vector, pSpCas9(BB)-2A-
GFP (pX458), which was obtained from Feng Zhang lab (Addgene plasmid # 48138) 
(Ran et al., 2013). Plasmid pX458 is a CRISPR plasmid that expresses Green 
Fluorescence Protein (GFP) (Figure 2.1). The GFP in this plasmid was used to monitor 
transfection efficiency in cells lines.  
 
Figure 2.1 Plasmid pSpCas9(BB)-2A-GFP (pX458) that expresses Green 
Fluorescence Protein (GFP) 
 
 22 
 
The protocol used for cloning was as described by Cong et al. 2013. Briefly, 
pX458 was digested with BbsI. Then, the OTUB1 oligonucleotides (gRNAs) were 
phosphorylated and annealed in a thermocycler, similar to previous studies (Cong et al. 
2013). This was followed by a ligation step as detailed below for oligo annealing and 
cloning into backbone vectors: 
 Firstly, digest 1µg of pX458 with BbsI for 30 min at 37C using this mixture: 
   
   
 
 
 
 1 µg pX458 
 1 µl FastDigest BbsI (Fermentas) 
 1 µl FastAP (Fermentas) 
 2 µl 10X FastDigest Buffer 
 X µl ddH2O 
 20 µl Total 
 
Secondly, gel purify digested pX458 using QIAquick Gel Extraction Kit and elute in 
water. After that, phosphorylate and anneal each pair of oligos using these components: 
 1 µl Oligo 1 (100mM) 
 1 µl Oligo 2 (100mM) 
 1 µl  10X T4 Ligation Buffer (NEB) 
 6.5 µl ddH2O 
 0.5 µl T4 PNK (NEB) 
 10 µl Total 
Then, anneal in a thermocycler using the following parameters: 
 37oC   30 min 
95oC   5 min and then ramp down to 
25oC   5oC/min 
 
Lastly, set up ligation reaction and incubate at room temperature for 10 min: 
 X µl BbsI digested pX458 step 2 (50 ng) 
 1 µl Phosphorylated and annealed oligo duplex from step 3 (1:200 dilution) 
 5 µl 2X Quickligation Buffer (NEB) 
 X µl ddH2O 
 10 µl Subtotal 
 1 µl Quick Ligase (NEB) 
 11 µl Total 
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The cloned vector was then transformed into DH5–alpha competent E.coli (NEB). 
For High Efficiency Transformation Protocol, thaw a tube of DH5–alpha competent 
E.coli (NEB) cells on ice for 10 minutes. Then, add 1–5 µl containing 1 pg–100 ng of 
plasmid DNA to the cell mixture. Carefully flick the tube 4–5 times to mix cells and 
DNA. Do not vortex. After that, place the mixture on ice for 30 minutes and do not mix. 
Heat shock at exactly 42°C for exactly 30 seconds and do not mix. Then, place on ice for 
5 minutes and do not mix.  
After that, pipette 950 µl of room temperature SOC into the mixture and place at 
37°C for 60 minutes. Shake vigorously (250 rpm) or rotate. At the same time, warm 
selection plates to 37°C. After 60 minutes, mix the cells thoroughly by flicking the tube 
and inverting, then perform several 10-fold serial dilutions in SOC. Lastly, spread 50–
100 µl of each dilution onto a selection plate and incubate overnight at 37°C. 
Alternatively, incubate at 30°C for 24–36 hours or 25°C for 48 hours. 
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2.1.2 Verification of CRISPR sequence 
12 colonies were picked from the agar plate in 2.1.1 and colony PCR was 
conducted to verify that the colonies contained the insert. Colony PCR was done using 
the forward primer hU6 (5’ – CAGCGACTCCGAAGGTGTTA – 3’) and CRISPR 
reverse primer (5’ – TGGTCTTGCGGATGTACGAG – 3’) with the following 
parameters. Detailed steps are as listed below. 
 
 
 
 
 
 95°C      5 minutes    1 cycle 
 95°C      0.5 minute 
 60°C      0.5 minute 
 72°C      1 minute 
 72°C      10 minutes    1 cycle 
   4°C      Hold until ready to proceed 
 
Amplicons were then run on a 1% agarose gel at 100 V for 30 minutes. A 650 
base pair amplicon would indicate that the colony contained the insert of interest. DNA 
of positive colonies were purified and sent to Integrated DNA Technologies (IDT) for 
DNA sequencing.  
 
 
 
 
 
PCR Colony Screening 
 
25 µl    Taq 2X Master Mix  
2µl    Forward Primer  
2µl    Reverse  
21µl    H20 
30 cycles 
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2.2 Cell culture and reagents 
In this study, three different cell types were used, MCF7 (breast cancer), Saos2 
(bone cancer) and HepG2 (liver cancer) cell lines.  
MCF7 and Saos2 cells were cultured in Gibco® Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific, 
Tarzana, CA) and 1% penicillin and streptomycin mixture (Pen-Strep) (Invitrogen). All 
cells were incubated at 37°C and 5% CO2. 
HepG2 cells were cultured in Gibco® RPMI 1640 medium supplemented with 
10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA) and 1% penicillin and 
streptomycin mixture (Pen-Strep) (Invitrogen). All cells were incubated at 37°C and 5% 
CO2. 
pQBI was used as the positive control, and untransfected cells were used as the 
negative control. pQBI was used as a positive control because of its constitutive GFP 
expression (Figure 2.2). 
 
Figure 2.2     Plasmid map of pQBI. pQBI is a plasmid that constantly expresses 
Green Fluorescence Protein (GFP) 
